STAT+: Drug makers already bet big on mRNA for cancer. Why is Biden going in, too?
WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its…
Category: Pharmaceuticals
STAT+: What past blockbusters can tell us about future of Wegovy and other weight loss medicines
The news that the weight loss drug Wegovy reduced the risk of heart attacks and…
Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech
The youngest candidate on Wednesday night’s debate stage didn’t make any friends among his fellow…
STAT+: Pharmalittle: Roche data on immunotherapy accidentally released; Novo Nordisk hires Thermo Fisher to manufacture Wegovy
Hello and happy Wednesday from STAT’s London outpost, with Andrew Joseph here filling in for…
STAT+: Obesity specialists are scarce. Here’s how that’s starting to change
Treatment of obesity has never been more prominent, with the advent of medications like Ozempic…
STAT+: FDA approves Pfizer’s RSV vaccine for newborns; Boehringer sues over IRA
Good morning, one and all. Damian Garde here, filling in for Ed Silverman once more…
STAT+: Pharmalittle: Regeneron wins a delayed approval; Bristol, J&J likely to face pricing negotiation
Good morning, everyone. Damian Garde here, filling in for Ed Silverman on yet another dog…
STAT+: ViiV Healthcare and Doctors Without Borders tussle over contract terms for an HIV drug
A feud has erupted between ViiV Healthcare and Doctors Without Borders over a deal to…
STAT+: U.S. appeals court strike down key provisions in Oklahoma law that regulates PBMs
A U.S. appeals court struck down key parts of an Oklahoma law designed to regulate…
STAT+: ActiGraph executives on why getting digital endpoints approved for drug trials matters
As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become…
STAT+: Health care CEOs hauled in $4 billion last year as inflation pinched workers, analysis shows
The health care industry didn’t just provide a safe haven for jittery stock investors in…
.jpg)
STAT+: FDA warns AstraZeneca over misleading promotional materials for a COPD drug
The U.S. Food and Drug Administration scolded AstraZeneca for making misleading claims about the effectiveness…
STAT+: SEC wants to know if key supplier of research monkeys bribed foreign officials
A U.S. government probe into a monkey-smuggling operation emanating from Cambodia has gone in a…
STAT+: BMS, looking to build a market for a heart drug, turns to a Viz.ai algorithm to detect disease
As Bristol Myers Squibb works to build its treatment for a heart condition that can…
Opinion: The best way for the NIH to reduce drug prices is to address drug spending
As STAT reported recently, the Senate Committee on Health, Education, Labor, and Pensions (HELP) has…
STAT+: More hospital pharmacists are rationing drugs due to increasing shortages
Nearly every hospital pharmacy across the U.S. is experiencing shortages of prescription drugs. And the…
STAT+: White House drug shortages task MIA with lawmakers while Congress works on fixes
WASHINGTON — A White House task force created to work on drug shortage reforms has…
Opinion: Philanthropic endowments at universities can offer a way out of biotech’s Valley of Death
So many promising medical innovations never reach their full potential as therapies or cures, languishing…
STAT+: EPA fines Roche’s Genentech unit for hazardous waste violations
Following an extensive inspection, the U.S. Environmental Protection Agency fined Genentech more than $158,000 for…
STAT+: What to know about concerns raised about compounded versions of Novo Nordisk’s Wegovy
As demand for Ozempic and Wegovy surges, a little noticed warning about the medicines was…
Listen: Your guide to Wegovy’s blockbuster heart study
Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And…
STAT+: Novo acquires Inversago for up to $1 billion, spotlighting troubled weight loss approach
Fresh off of the news that its drug Wegovy may not just help people lose…
STAT+: Telehealth companies are driving a large share of weight loss drug prescriptions, claims data suggest
As a new class of obesity medications has soared in popularity, so have the online…
STAT+: Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform
WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental…
Opinion: STAT+: What Mark Cuban gets wrong about prescription drugs
Mark Cuban, the Dallas Mavericks owner and “Shark Tank” star, has been making headlines recently…
STAT+: Novo Nordisk celebrates landmark Wegovy study, even as supply issues persist
The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives…
Nonprofit naloxone maker celebrates FDA approval by donating 200,000 doses
A nonprofit naloxone manufacturer is celebrating its recent market approval by giving away 200,000 doses…
Opinion: Public pharma is the best solution to the ongoing problem of drug shortages
Drug shortages in the United States are at a record high. At least 14 essential…
.jpg)
Opinion: STAT+: One way to create resilient drug supply chains: incentivize predictive models
My first exposure to pharmaceutical shortages happened in 2017 as a new-to-practice nurse working on…
STAT+: Wegovy’s successful heart trial raises a vital question about weight loss
A landmark study that found the blockbuster obesity drug Wegovy reduces the chance of heart…
Failed clinical trials don’t always spell doom for a new drug. Here’s why
This article was adapted from STAT’s latest report, “Failed trial, successful drug: how a negative…
STAT+: More drugmakers are filing continuation patents that sideline generic competition
Amid concerns that the pharmaceutical industry unfairly wins monopolies on medicines, a new analysis finds…
STAT+: Novo’s obesity drug Wegovy lowers cardiovascular risk by 20%, landmark trial finds
Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in…
STAT+: More regulation could be coming for drug ads
WASHINGTON — Government regulators may soon decide whether to crack down on distracting visuals in…
STAT+: Nektar Therapeutics sues Lilly for ‘misconduct’ in drug development deal
A behind-the-scenes feud over a drug development program erupted into public view as Nektar Therapeutics…
Listen: Biotech layoffs, eye drug drama, & gene therapy milestones
Can biotech startups survive a downturn? Is Covid-19 a good business? And when did ophthalmology…
STAT+: Vertex faces renewed calls to widen access to its cystic fibrosis medicines in poor countries
Several Latino advocacy groups and more than 100 clinicians from dozens of countries are lending…
STAT+: White House drug shortage task force held rare in-person meeting with industry
WASHINGTON — A new White House task force on drug shortages held a rare in-person…
STAT+: Pharma industry showers House GOP doctor with campaign cash
WASHINGTON — The pharmaceutical industry has been flooding the campaign coffers of Rep. Larry Bucshon, a…
STAT+: Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle
Patients are bracing for “D-Day,” the date their insurance companies will stop covering the drugs….
STAT+: Intas Pharma employee used acid to destroy manufacturing records at troubled plant
Last November, an employee at Intas Pharmaceuticals, which makes several widely used chemotherapies that are…
Opinion: I learned the hard way that U.S. airlines are not currently required to have EpiPens
I was in seat 20C on a flight home this March, when I felt my…
Opinion: New attacks on the drug industry would have made my breakthrough sickle cell treatment impossible
I was born in Alabama in the Jim Crow South, one of eight siblings in…
STAT+: House GOP offers new plan to stem drug shortages, including cancer drug shortages
WASHINGTON — House Republicans have drafted drug-shortage legislation that differs significantly from the approach Democrats…
STAT+: Policy experts call on Medicare to ensure data from Alzheimer’s drug registries is shared publicly
More than two dozen prominent health policy experts are urging the Biden administration to ensure…
STAT+: How the first over-the-counter birth control pill in the U.S. got its ‘unapologetic’ design
It’s not every day that a marketing team is tasked with designing the branding and…
STAT+: Senate panel advances PBM reform — but sidesteps anything controversial
WASHINGTON — Senators on the Finance Committee on Wednesday nearly unanimously passed a bill to…
STAT+: European Commission accelerates phasing out animal testing, but stops short of a ban
After months of deliberation, the European Commission has agreed to accelerate the phasing out of…
STAT+: Democrats already want to expand Medicare’s drug price negotiation
WASHINGTON — It’s drug pricing déjà vu: Just as they did in 2019, House Democrats…
STAT+: FDA inspection underscores problem at major U.S. compounder behind hospital drug recalls
One of the largest compound pharmacy operations in the U.S. recently recalled a slew of…